Animal models of intestinal inflammation: New insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease

International Journal of Colorectal Disease

Volumn 15, Issue 3, 2000, Pages 144-160

  Wirtz, S ^a   Neurath, M F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Animal models; Cytokines; Inflammatory bowel disease

Indexed keywords

ALPHA INTERFERON; AUTACOID; BACTERIAL ANTIGEN; CD4 ANTIGEN; CELL ADHESION MOLECULE; COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6 RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE SIMULATION; ENTERITIS; ENVIRONMENTAL FACTOR; EXPERIMENTAL ANIMAL; HEREDITY; IMMUNOREGULATION; IMMUNOTHERAPY; INTESTINE FUNCTION; MEDIATOR; MOLECULAR BIOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL;

ANIMALS; ANTIGENS, CD4; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MICE; MICE, TRANSGENIC; SAGUINUS; T-LYMPHOCYTES;

EID: 0033830605     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003840000227     Document Type: Review

References (139)

1. Inflammatory bowel disease. I
2. The genetics of inflammatory bowel disease
3. Experimental models of inflammatory bowel disease
4. The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease
5. The anatomical basis of intestinal immunity
6. Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice
7. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease
8. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis
9. Characterization of spontaneous colitis in cotton-top tamarins (Saguinus oedipus) and its response to sulfasalazine
10. Evolution of the MHC class I genes of a New World primate from ancestral homologues of human non-classical genes
11. A primate species with limited major histocompatibility complex class I polymorphism
12. Immune-complex mediated colitis in rabbits. An experimental model
13. Chronic immune colitis in rabbits
14. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis
15. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis
16. Effects of 16:16-dimethyl prostaglandin E2 and indomethacin on leukotriene B4 and inflammation in rabbit colitis
17. Experimental production of diffuse colitis in rats
18. Effect of ingestion of eicosapentaenoic acid ethyl ester on carrageenan-induced colitis in guinea pigs
19. Rapid production of ulcerative disease of the colon in newly-weaned guinea-pigs by degraded carrageenan
20. Bacteroides vulgatus outer membrane antigens associated with carrageenan-induced colitis in guinea pigs
21. Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: Similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors
22. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin
23. Systemic uptake and intestinal inflammatory effects of luminal bacterial cell wall polymers in rats with acute colonic injury
24. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats
25. Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers
26. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice
27. Promotion of colorectal neoplasia in experimental murine ulcerative colitis
28. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice
29. Protection from radiation-induced colitis requires MHC class II antigen expression by cells of hemopoietic origin
30. Hapten-induced model of chronic inflammation and ulceration in the rat colon
31. Hapten-induced model of murine inflammatory bowel disease: Mucosa immune responses and protection by tolerance
32. Antibodies to interleukin 12 abrogate established experimental colitis in mice
33. A comparative analysis of two models of colitis in rats
34. Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses
35. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance
36. Intestinal inflammation in adhesion molecule-deficient mice: An assessment of P-selectin alone and in combination with ICAM-1 or E-selectin
37. A synthetic mimetic of CD4 is able to suppress disease in a rodent model of immune colitis
38. Protection of trinitrobenzene sulfonic acid-induced colitis by an interleukin 2-IgG2b fusion protein in mice
39. The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis
40. Oxazolone-induced colitis in rats: Effects of budesonide, cyclosporin A, and 5-aminosalicylic acid
41. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4
42. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells
43. Mucosal immunity and inflammation. II. The yin and yang of T cells in intestinal inflammation: Pathogenic and protective roles in a mouse colitis model
44. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice
45. In vitro activated CD4+ T cells from interferon-gamma (IFN-gamma)-deficient mice induce intestinal inflammation in immunodeficient hosts
46. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells
47. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB (low) CD4+ T cells
48. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells
49. CD45RBhigh CD4+ T cells from IFN-gamma knockout mice do not induce wasting disease
50. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
51. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients
52. Blockade of IL-6 trans-signaling abrogates established experimental colitis in mice by suppression of T cell resistance against apoptosis
53. Severe colitis in mice with aberrant thymic selection
54. A block in both early T lymphocyte and natural killer cell development in transgenic mice with high-copy numbers of the human CD3E gene
55. Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells
56. Cytokine gene deleted mice in the study of gastrointestinal inflammation
57. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: An animal model of HLA-B27-associated human disorders
58. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats
59. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats
60. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats
61. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice
62. Chronic intestinal inflammation in STAT-4 transgenic mice: Characterization of disease and adoptive transfer by TNF-plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens
63. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin
64. The serum factor from patients with ulcerative colitis that induces T cell proliferation in the mouse thymus is interleukin-7
65. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa
66. IL-7 deficiency prevents development of a non-T cell non-B cell-mediated colitis
67. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice
68. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
69. T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice
70. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation
71. Induction and prevention of colonic inflammation in IL-2-deficient mice
72. Interleukin-10-deficient mice develop chronic enterocolitis
73. Altered immune responses in interleukin 10 transgenic mice
74. Studies with IL-10-/-mice: An overview
75. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice
76. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice
77. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor
78. Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice
79. G (alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines
80. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease
81. The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice
82. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment
83. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis
84. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor
85. A novel model of inflammatory bowel disease: Mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis
86. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation
87. Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet?
88. Enhanced Th 1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils
89. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
90. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
91. T cells in mouse models of gut inflammation
92. Cytokines induce the development of functionally heterogeneous T helper cell subsets
93. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease
94. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease
95. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells
96. Regulatory T cells and inflammatory bowel disease
97. CD4+ T cell down-regulation in human intestinal mucosa: Evidence for intestinal tolerance to luminal bacterial antigens
98. T cell immunity to oral allergens
99. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5
100. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12
101. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli
102. A novel urease-negative Helicobacter species associated with colitis and typhlitis in IL-10-deficient mice
103. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism
104. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice
105. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative?
106. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
107. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
108. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
109. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody
110. Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-/-mice
111. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7
112. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice
113. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
114. ICAM-1 antisense therapy: A new treatment concept on Crohn disease? Placebo controlled study of ICAM-1 antisense oligonucleotide therapy in Crohn disease
115. Viral vectors expressing immunoregulatory cytokines to treat inflammatory bowel disease
116. Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure
117. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells
118. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease
119. Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis
120. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease
121. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats
122. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis
123. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease)
124. Attenuation of the inflammatory response in an animal colitis model by neutrophil inhibitory factor, a novel beta 2-integrin antagonist
125. Efficacy of recombinant granulocyte colony-stimulating factor (rhG-CSF) in experimental colitis
126. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice
127. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice
128. Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice
129. Role of cytokines in the early stages of chronic colitis in TCR alpha-mutant mice
130. Granulocyte infiltration in experimental colitis in the rat is interleukin-1 dependent and leukotriene independent
131. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)
132. Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats
133. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody
134. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAd-CAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells
135. Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats
136. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice
137. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: Amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein
138. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
139. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides